Plasminogen Activator Inhibitor-1 in Skin Malignancies: Therapeutic Implications of Its Inhibition

Plasminogen activator inhibitor-1 (PAI-1), a key regulator of fibrinolysis, has emerged as a critical stromal factor that contributes to tumor progression in various malignancies, including skin cancers. Beyond its classical role in inhibiting plasminogen activators, PAI-1 exerts pleiotropic effects...

Full description

Bibliographic Details
Published in:	Biomolecules
Main Authors:	Taku Fujimura, Yusuke Muto, Yoshihide Asano
Format:	Article
Language:	English
Published:	MDPI AG 2025-09-01
Subjects:	PAI-1 tumor microenvironment SASP melanoma immune checkpoints angiogenesis
Online Access:	https://www.mdpi.com/2218-273X/15/9/1317

Similar Items

Construction of a prognostic risk-scoring model based on SASP-related genes in patients with skin cutaneous melanoma
by: Ming-Feng Li, et al.
Published: (2025-08-01)

Cellular senescence and SASP in tumor progression and therapeutic opportunities
by: Zening Dong, et al.
Published: (2024-08-01)

Angiogenic inhibitor pre‐administration improves the therapeutic effects of immunotherapy
by: Mineyoshi Sato, et al.
Published: (2023-04-01)

PLASMINOGEN ACTIVATOR INHIBITOR GENE POLYMORPHISM IN EVALUATION OF THE VARIOUS LOCALIZATION THROMBOSIS RISKS (PILOT STUDY)
by: A. I. Subbotovskaya, et al.
Published: (2015-10-01)

Treatment of Advanced Melanoma: Past, Present and Future
by: Taku Fujimura, et al.
Published: (2020-09-01)

Bone Marrow Senescence and the Microenvironment of Hematological Malignancies
by: Charlotte Hellmich, et al.
Published: (2020-02-01)

Targeting senescence‐associated secretory phenotypes to remodel the tumour microenvironment and modulate tumour outcomes
by: Jiaqiang Xiong, et al.
Published: (2024-09-01)

The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer
by: Taku Fujimura
Published: (2025-08-01)

Papular interstitial elastolytic giant cell granuloma concomitant with lichen amyloidosus in a type II diabetes patient
by: Saki Hiwatashi‐Okuda, et al.
Published: (2023-09-01)

IFN-γ and TNF Induce Senescence and a Distinct Senescence-Associated Secretory Phenotype in Melanoma
by: Lorenzo Homann, et al.
Published: (2022-04-01)

The crosstalk between senescence, tumor, and immunity: molecular mechanism and therapeutic opportunities
by: Zehua Wang, et al.
Published: (2025-01-01)

Immunological and senescence biomarker profiles in patients after spontaneous clearance of hepatitis C virus: gender implications for long-term health risk
by: Rubén Martín-Escolano, et al.
Published: (2023-11-01)

Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes
by: Zexing Shan, et al.
Published: (2024-07-01)

Exosomal Plasminogen Activator Inhibitor-1 Induces Ionizing Radiation-Adaptive Glioblastoma Cachexia
by: Eunguk Shin, et al.
Published: (2022-10-01)

Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma
by: Vincenzo Ingangi, et al.
Published: (2024-06-01)

Recent advances in dermal fibroblast senescence and skin aging: unraveling mechanisms and pioneering therapeutic strategies
by: Li Nan, et al.
Published: (2025-06-01)

Plasminogen activator inhibitor-1 polymorphisms as a risk factor for chronic periodontitis in North Indian population
by: Puja Debnath, et al.
Published: (2019-04-01)

Hallmarks and Biomarkers of Skin Senescence: An Updated Review of Skin Senotherapeutics
by: Darya Bulbiankova, et al.
Published: (2023-02-01)

Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1
by: Abd Aziz Ibrahim, et al.
Published: (2024-05-01)

Urokinase-type Plasminogen Activator and Plasminogen Activator Inhibitor Induction by Etoposide in a Glioblastoma Cell Strain
by: Branko Brdar, et al.
Published: (2002-01-01)

Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma
by: Wengang Zhang, et al.
Published: (2022-11-01)

Cellular Senescence and Periodontitis: Mechanisms and Therapeutics
by: Sijia Chen, et al.
Published: (2022-09-01)

Plasminogen activator inhibitor-2 (PAI-2) overexpression supports bladder cancer development in PAI-1 knockout mice in N-butyl-N- (4-hydroxybutyl)-nitrosamine- induced bladder cancer mouse model
by: Hideki Furuya, et al.
Published: (2020-02-01)

Eosinophilic granulocytes as a potential prognostic marker for cancer progression and therapeutic response in malignant melanoma
by: Corsin Linard Brand, et al.
Published: (2024-05-01)

Impact of Plasminogen Activator Inhibitor-1 Serum Levels and the -675 4G/5G Variant in the SERPINE1 Gene on Systemic Sclerosis in a Mexican Population
by: José Alvaro Lomelí-Nieto, et al.
Published: (2024-08-01)

Urokinase-Type Plasminogen Activator System in Norm and in Life-Threatening Processes (Review)
by: Elena V. Kugaevskaya, et al.
Published: (2018-12-01)

Molecular and Genetic Markers for Malignant Melanoma: Implications for Prognosis and Therapy
by: Lauren Fleshner, et al.
Published: (2025-09-01)

Serum CCL22 Increased in Advanced Melanoma Patients with Liver Metastases: Report of 5 Cases
by: Kentaro Ohuchi, et al.
Published: (2022-12-01)

Interactions between oxidative stress and senescence in cancer: Mechanisms, therapeutic implications, and future perspectives
by: Dengxiong Li, et al.
Published: (2024-07-01)

Clinical and diagnostic significance of plasminogen activator inhibitor type 1 in the early development of coronary heart disease
by: Nargiza M. Nurillaeva, et al.
Published: (2023-02-01)

Quercetin Alleviates Pulmonary Fibrosis in Mice Exposed to Silica by Inhibiting Macrophage Senescence
by: Fei Geng, et al.
Published: (2022-07-01)

Tumor Microenvironmental Dynamics in Shaping Resistance to Therapeutic Interventions in Melanoma: A Narrative Review
by: Laci M. Turner, et al.
Published: (2025-07-01)

The redox-senescence axis and its therapeutic targeting
by: Natalie YL. Ngoi, et al.
Published: (2021-09-01)

Cytokines, Chemokines, and Other Biomarkers of Response for Checkpoint Inhibitor Therapy in Skin Cancer
by: Jennifer A. Bridge, et al.
Published: (2018-12-01)

The role of cellular senescence in skin aging and age-related skin pathologies
by: Toby Chin, et al.
Published: (2023-11-01)

CDK4/6 inhibitors induce breast cancer senescence with enhanced anti‐tumor immunogenic properties compared with DNA‐damaging agents
by: Dong Hyun Lee, et al.
Published: (2024-01-01)

Recent Advances in Aging and Immunosenescence: Mechanisms and Therapeutic Strategies
by: Shuaiqi Wang, et al.
Published: (2025-03-01)

Cellular senescence in asthma: from pathogenesis to therapeutic challenges
by: Rongjun Wan, et al.
Published: (2023-08-01)

The role of bone marrow microenvironment (BMM) cells in acute myeloid leukemia (AML) progression: immune checkpoints, metabolic checkpoints, and signaling pathways
by: Maryam Bakhtiyari, et al.
Published: (2023-09-01)

Interplay between epigenetics, senescence and cellular redox metabolism in cancer and its therapeutic implications
by: Geoffrey Balamurli, et al.
Published: (2024-12-01)